Controlled administration of dehydrochloromethyltestosterone in humans: Urinary excretion and long-term detection of metabolites for anti-doping purpose

Detectability of oxandrolone, metandienone, clostebol and dehydrochloromethyltestosterone in urine after transdermal application

“…Concerning DHCMT, literature data after oral uptake indicate traceability of metabolites M2, M3, 6-OH-DHCMT and DHCMT glucuronide. 28 On the contrary to literature data after an oral uptake, presented data show clearly elongated detectability of DHCMT glucuronide on the one hand and missing presence of M2 metabolite on the other hand after transdermal application. Herein, DHCMT glucuronide was traceable up to 14 days after application, whereby a detectability of 6 days was investigated by Loke et al 28 Moreover, with respect to the presented data, the absence of the M2 metabolite can be assumed to be a strong indicator for transdermal DHCMT administration.…”

“…Concerning DHCMT, literature data after oral uptake indicate traceability of metabolites M2, M3, 6‐OH‐DHCMT and DHCMT glucuronide 28 . On the contrary to literature data after an oral uptake, presented data show clearly elongated detectability of DHCMT glucuronide on the one hand and missing presence of M2 metabolite on the other hand after transdermal application.…”

“…In the other two experiments, M1 findings were obtained over a period of approximately 6–8 h up to 7 days or even 11 days after transdermal application, indicating a long detection time of the substance. Studies concerning the metabolic patterns after oral administrations of different doping agents have been published in the past years 26–31 and will be considered for the comparison of metabolic patterns after transdermal and oral substance uptake.…”

“…In the other two experiments, M1 findings were obtained over a period of approximately 6-8 h up to 7 days or even 11 days after transdermal application, indicating a long detection time of the substance. Studies concerning the metabolic patterns after oral administrations of different doping agents have been published in the past years[26][27][28][29][30][31] and will be considered for the comparison of metabolic patterns after transdermal and oral substance uptake.Consequently, the presented case of Therese Johaug and lack of further comparative studies underline the relevance of further investigations regarding the possibility of positive test results after intentional or unintended transdermal exposure to prohibited doping substances.Thus, the aim of this study was to assess whether the detection of a subset of AAS (and respective metabolites) in human urine can be reconcilable with a transdermal drug exposure event, whether or not intentional or inadvertent. With respect to cases, where athletes claimed an inadvertent exposure to doping agents that might have been caused by a covert administration, investigating whether an administration of substances via a hand shake or a brief contact of other body parts is compatible with doping control analytical data appears warranted.…”

Annual banned‐substance review: Analytical approaches in human sports drug testing 2020/2021

“…The elimination profile of DHCMT in males was systematically investigated by Loke et al, 60 confirming the utility of formerly identified long-term metabolites and, furthermore, demonstrating substantial inter-individual variability of the drug's metabolism and elimination. The most commonly monitored metabolite of DHCMT (referred to as 4α-chloro-17β-hydroxymethyl-17α-methyl-18-nor-5αandrostan-13-en-3α-ol) was corroborated as a suitable urinary longterm marker for the intake of the banned AAS, but complementing routine testing protocols by additional metabolites of both fractions, glucuronidated and unconjugated, was found advisable.…”